Association between plasma bilirubin and mortality
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F19%3A00078394" target="_blank" >RIV/00023001:_____/19:00078394 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/19:10398674
Result on the web
<a href="https://reader.elsevier.com/reader/sd/pii/S1665268119300237?token=FFDB9C143184520B7340EED90B4B1DB29EB78BFE07AEC8AD6D58927262D6A7FF2BB71803C3815BCF75C985CC72E5B88C" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S1665268119300237?token=FFDB9C143184520B7340EED90B4B1DB29EB78BFE07AEC8AD6D58927262D6A7FF2BB71803C3815BCF75C985CC72E5B88C</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.aohep.2019.02.001" target="_blank" >10.1016/j.aohep.2019.02.001</a>
Alternative languages
Result language
angličtina
Original language name
Association between plasma bilirubin and mortality
Original language description
Introduction and aim: It has been proposed that plasma concentration of bilirubin, an endogenous antioxidant, is protective against diseases mediated by increased oxidative stress, including cardiovascular diseases (CVD) and cancer. To examine this hypothesis, we investigated the relationship between plasma bilirubin concentrations and bilirubin UDP-glucuronosyl transferase (UGT1A1) promoter gene variations (associated with increased bilirubin concentrations) with total/CVD and cancer mortality. Materials and methods: A nested case-control study was conducted within the Polish arm of the HAPIEE cohort. At baseline in 2002-2005, participants were examined in detail. Mortality follow-up (median (IQR) between blood draw and death was 3.7 (2.1-5.1) years) was performed by linkage with regional and national death registers. Plasma biomarkers were analysed in all subjects who died from any cause (cases, n = 447) and in a random subsample of survivors (controls, n = 1423). Results: There was a strong negative association between plasma bilirubin levels and total and cancer mortality, expressed more profoundly in men. The adjusted OR of deaths from all causes and cancer, comparing the highest vs. lowest plasma bilirubin categories were 0.61 (95% CI: 0.42-0.87) and 0.39 (0.24-0.65), respectively. There was no association of bilirubin with CVD mortality. The UGT1A1*28 allele, a genetic marker of raised bilirubin, was also negatively associated with total/cancer mortality, although the associations were not statistically significant. Discussion: Both the observational and genetic associations support the negative relationship between bilirubin and total mortality; this association appears to be driven by cancer mortality, while that with CVD mortality is not evident. (C) 2019 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
<a href="/en/project/NV15-28895A" target="_blank" >NV15-28895A: Bilirubin as a risk factor of cardiovascular disease development.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of hepatology
ISSN
1665-2681
e-ISSN
—
Volume of the periodical
18
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
379-385
UT code for WoS article
000482887100018
EID of the result in the Scopus database
2-s2.0-85066163619